Mepolizumab
- SubcutMepolizumabNucala
Mechanism of Action
- A humanised monoclonal antibody directed against IL-5, a cytokine that stimulates maturation, growth and activation of eosinophils.
Clinical Use
Indications
- Severe refractory eosinophilic asthma.
- Adverse Effects
- Injection site reactions
- Upper respiratory tract infections
- Myalgias
- Fatigue